dBio Appoints Hubertus ‘Bert’ Hoyt as Board Advisor
LUXEMBOURG, April 23, 2025 – Decentralized Biotechnology Intelligence Holding Group Inc. (dBio), a leading innovator in sports and health tech, has announced the appointment of Hubertus “Bert” Hoyt as its newest Board Advisor. Hoyt, a renowned sports industry expert with over 32 years of experience, brings invaluable strategic insights to dBio’s Board.
Bert Hoyt’s extensive background working with iconic sports brands and elite athletes will support dBio’s mission to revolutionize personalized healthcare and fitness technologies worldwide. dBio’s proprietary technologies include gMOTCloud, an AI-powered kinesiology wearable, and StethoCloud, a lightweight wearable stethoscope with AI-enhanced noise reduction. These devices offer cloud-based analytics and virtual coaching support for healthier performance in exercise.
With more than 75 registered patents and a fully self-developed ecosystem, dBio delivers comprehensive solutions for performance optimization and health management. The company’s technology is supported by strategic partnerships with leaders in the medical, academic, and athletic sectors.
Bert began his career at Puma in 1989 and later joined Nike in 1998, where he spent 22 years as a senior executive. He was instrumental in transforming Nike Germany, Global Football, and Western Europe, leading Nike EMEA to market leadership. Since retiring from Nike in 2021, Bert has served as a non-executive Director at several companies, including JD Sports PLC and Cosnova GmbH.
“I’ve been involved in helping athletes improve their performance and overall well-being throughout my personal and business life,” Bert said. “That’s why I decided to join dBio as an Advisor, as I believe their innovations will provide the next chapter for athlete performance and help sports enthusiasts manage their overall well-being.”
dBio continues to expand its global footprint, aiming to redefine the future of personalized health and performance technology.
